What’s New
Prostate Cancer Treatment — Lutetium (Lu-177) Hearty Patient Support Scheme
2026/11/16

Prostate Cancer Treatment — Lutetium (Lu-177) Hearty Patient Support Scheme

Additional Support to bring extra strength to your treatment

Like other cancer patients, prostate cancer patients are facing undue stress on treatment options and may also the related financial burden.

To relieve the financial stress of patients, Hong Kong Baptist Hospital offers Lutetium (Lu-177) Hearty Patient Support Scheme (“Hearty Scheme”) for eligible and approved patients to receive Lu-177 (RIT) radioligand therapy at a privileged package price.Patients can access a hospital-grade, one-stop comprehensive assessment and treatment pathway commencing from HKBH East Kowloon Medical Centre.

 

Treatment package: HK$120,000/ treatment

Package Includes: 

  • Electrocardiogram (ECG).
  • Designated inpatient medications included in the package.
  • Blood tests (RLFT, CBC).
  • Lu-177 radioligand therapy (according to package arrangements).
  • The first doctor’s consultation at the EKMC Oncology & Chemotherapy Day Centre.
  • Doctor’s Consultation Fee (HKD 1,500 per consultation).

 

Eligibility Criteria*
Applicants must meet all of the following criteria for approval from the Hospital:

  • Hong Kong permanent resident.
  • Average monthly income of HKD 60,000 or below.
  • • Own no property in Hong Kong, or own only one residential property that is self-occupied.
  • Submit relevant income proof for assessment and approval.

* This scheme has no insurance restrictions.
* Meeting the above criteria does not guarantee approval. The hospital will review and approve applications based on the information submitted and the scheme criteria.

 

Complimentary First Consultation Support
The first 20 eligible cases will receive one complimentary first consultation, on a first-come, first-served basis.

  • A referral letter and/or relevant medical reports must be submitted.
  • Cases may first be screened by the nursing team at the EKMC Oncology & Chemotherapy Day Centre.
  • The first consultation must take place at the EKMC Oncology & Chemotherapy Day Centre.

 

Payment Arrangements

  • All payment records and receipts must be submitted, and will be verified by the HKBH Finance Department.
  • Payment can be made through the Hospital’s designated payment methods, including online payment.
  • Patients must pay the full package fee before ordering the medication and scheduling the treatment.

 

 

One-Stop Follow-Up from Application to Treatment

1|Contact the Centre & Preliminary Screening
Please contact the EKMC Oncology & Chemotherapy Day Centre for r enquiries, and submit a referral letter and/or relevant medical reports. Our nursing team may first conduct an initial screening to assess whether the patient is suitable for further evaluation.

 

2| First Consultation at EKMC*
The first consultation must be take place at the EKMC Oncology & Chemotherapy Day Centre, where a doctor will evaluate your clinical need and suitability for the treatment.
*The first 20 eligible cases will receive one complimentary first consultation, on a first-come, first-served basis.

 

3|Submit Scheme Application*
Please complete and sign the application form, and submit the required documents:

  • Relevant income proof.
  • Copies of salary records/pay slips for the past 3 months (if applicable).

*The hospital may request additional information to complete the vetting process.

 

4|Eligibility Vetting & Result Notification
The relevant departments will verify the application details and evaluate eligibility based on the scheme criteria. The Centre will notify the applicant of the result.

 

5|Payment &Treatment Scheduling
Upon approval and confirmation of the treatment plan, the patient must settle the full package fee before the medication can be ordered and the treatment scheduled. The medical team will follow up on the required tests and treatment workflow.


Please note: Whether the treatment is medically suitable for you and whether your support scheme application is approved are two separate and independent evaluations.

 

 

How to Submit Your Application
Please contact our Centre first to confirm the application arrangements. The application form and required documents can be submitted in the following methods:

By Post or In Person Address:
Oncology & Chemotherapy Day Centre, 26/F,
HKBH East Kowloon Medical Centre,
8 Yan Yip Street, Kwun Tong, KowloonPlease mark the envelope:
“Prostate Cancer Treatment – ‘Lutetium’ Hearty Patient Support Scheme”

By Email chemoek@hkbh.org.hk

 

Important Notes

  • Applicants must provide true, accurate, complete information, and proactively notify the hospital of any changes to the relevant information.
  • Personal data will be handled in accordance with the Personal Information Collection Statement detailed in the application form.
  • All applications are subject to vetting; Hong Kong Baptist Hospital reserves the right of final approval.
  • The information of this website is for general reference only and cannot replace individual evaluation and advice from a doctor.

 

 

For Enquiry
“Lutetium” Hearty Patient Support Scheme|Eligibility Criteria | Application Arrangements
Tel:2339 8192
WhatsApp Enquiry:6146 6863

Know More About Lutetium-177 (Lu-177) PSMA Therapy

Lu-177 PSMA targeted radioligand therapy is a type of nuclear medicine treatment. It utilizes a drug labelled with the radioactive isotope Lutetium-177 to deliver targeted radiation directly to tumor cells that express Prostate-Specific Membrane Antigen (PSMA).

 

How Does the Treatment Work?

  • Target Identification: The targeting molecules in the drug bind specifically to the PSMA proteins on the surface of the tumor cells.
  • Radiation Delivery: Lutetium-177 delivers short-range beta radiation to disrupt tumor cell DNA, leading to cell death.

 

Am I Suitable for This Treatment?
Not all prostate cancer patients are suitable for Lu-177 PSMA therapy. A specialist will perform a comprehensive evaluation based on the following factors:

  • PSMA PET-CT scan results.
  • The extent of cancer metastasis and response to previous treatments.
  • Overall health condition, blood cell counts, and kidney function.

 

Understanding Treatment Risks
Common side effects: Dry mouth, fatigue, and nausea.
Potential risks: Drop in blood cell counts and impact on kidney function. Patients must undergo regular blood tests and monitoring as instructed by medical staff.

Treatment efficacy and side effects vary from person to person. After treatment, patients must strictly follow the radiation safety and home care guidelines provided by the medical staff.

Booking
Services
Fees & Charges
Doctors
Contact Us
Back to Top
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage.
Accept all
Reject all
Only necessary cookies